Shilpa Medicare's Q2 FY 2025-26 Quarterly Results

Result Summary

• Shilpa Medicare Ltd reported a 13.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 6.6%.
• Its expenses for the quarter were up by 10.7% QoQ and down 1.4% YoY.
• The net profit decreased 6.0% QoQ and increased 145.5% YoY.
• The earnings per share (EPS) of Shilpa Medicare Ltd stood at 2.25 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Shilpa Medicare Ltd is a well-established player in the pharmaceutical industry, known primarily for its production of generic drugs and active pharmaceutical ingredients (APIs). The company's portfolio includes a wide range of therapeutic categories, with a significant focus on the oncology segment. Shilpa Medicare Ltd has been actively involved in research and development to expand its product pipeline and improve its manufacturing capabilities. The company operates in a highly competitive industry, often influenced by regulatory changes and market dynamics. As of the latest available data, specific recent major developments or strategic expansions are not provided.

Revenue

For Q2FY26, Shilpa Medicare Ltd reported a total income of ₹371.72 crores, reflecting a quarter-over-quarter (QoQ) increase of 13.4% from ₹327.84 crores in Q1FY26. Compared to the same quarter in the previous year (Q2FY25), where total income was ₹348.79 crores, the company experienced a year-over-year (YoY) growth of 6.6%. This upward trend in total income indicates increasing sales or revenue generation capabilities over both the previous quarter and the prior year.

Profitability

The company recorded a profit before tax of ₹64.54 crores in Q2FY26, which is an improvement of 28.3% QoQ from ₹50.31 crores in Q1FY26 and a substantial increase of 73.7% YoY from ₹37.16 crores in Q2FY25. However, the profit after tax for Q2FY26 was ₹44.07 crores, marking a decrease of 6.0% QoQ compared to ₹46.89 crores in Q1FY26. Despite this, there was a significant YoY increase of 145.5% from ₹17.95 crores in Q2FY25. The tax expense for the quarter was significantly higher at ₹20.36 crores compared to previous periods, contributing to the decline in post-tax profitability on a sequential basis.

Operating Metrics

During Q2FY26, Shilpa Medicare Ltd's total expenses amounted to ₹307.18 crores, showing a QoQ increase of 10.7% from ₹277.52 crores in Q1FY26, but a slight YoY decrease of 1.4% from ₹311.62 crores in Q2FY25. Earnings per share (EPS) for the quarter stood at ₹2.25, reflecting a decrease of 53.0% QoQ from ₹4.79 in Q1FY26. However, there was a YoY increase of 23.0% from ₹1.83 in Q2FY25. The significant rise in tax expenses and its impact on profitability are notable aspects of the company's operating metrics, alongside the observed changes in EPS and expenses.